WASHINGTON — A combination of two immunotherapy drugs produced substantially higher rates of tumor eradication when added to chemotherapy before surgery in patients with high-risk, early-stage HER2-negative breast cancer, according to results from the adaptive I-SPY2 clinical trial platform. The regimen, however, will not move forward in its current form because investigators observed significant immune-related toxicities. The findings, published July 30, 2026, in JAMA Oncology, offer evidence that simultaneously targeting distinct immune-suppressive pathways may improve treatment responses while also highlighting the difficulty of combining powerful immunotherapies safely.
The phase 2 study evaluated cemiplimab and fianlimab alongside standard neoadjuvant chemotherapy. Neoadjuvant treatment is delivered before surgery, allowing physicians to measure how effectively a therapy eliminates cancer from the breast and nearby lymph nodes. Patients received weekly paclitaxel followed by doxorubicin and cyclophosphamide, while the immunotherapies were administered every three weeks. Surgery was performed after the drug treatment. The trial included adults with stage II or III disease considered at high risk of recurrence, including people with triple-negative breast cancer and those with hormone receptor–positive, HER2-negative tumors.
HER2-negative breast cancer is also described as ERBB2-negative breast cancer. ERBB2 is the gene that encodes the HER2 protein, a receptor involved in cell-growth signaling. When HER2 is overproduced, tumors can often be treated with HER2-directed drugs; when it is not, treatment generally relies on chemotherapy, endocrine therapy when hormone receptors are present, and increasingly, immunotherapy for selected patients. The I-SPY2 study was designed to identify promising combinations quickly by comparing investigational regimens with standard therapy and using early results to estimate whether a treatment might succeed in a larger phase 3 trial.
In the experimental arm, cemiplimab blocked PD-1, an inhibitory receptor on T cells. Tumors can exploit the PD-1 pathway to weaken immune-cell activity and avoid destruction. Fianlimab targeted LAG-3, another immune checkpoint that can suppress T-cell function when persistently activated. Blocking both pathways was intended to release complementary brakes on the immune response, potentially allowing immune cells to recognize and attack malignant cells more effectively than either approach alone. A total of 78 patients received the combination, while 350 participants were assigned to the control group.
The primary endpoint was pathologic complete response, or pCR, defined as the absence of residual invasive cancer in the breast and lymph nodes at surgery. Although pCR is not identical to long-term cure, it is strongly associated with a lower risk of recurrence in many high-risk breast cancers and is widely used to assess the effectiveness of preoperative treatment. Across all HER2-negative participants, the estimated pCR rate rose from 21% with standard therapy to 44% with the cemiplimab-fianlimab regimen. The result exceeded the I-SPY2 platform’s prespecified threshold for predicted success in a future phase 3 study.
The apparent benefit was observed in both major disease subgroups. Among patients with triple-negative breast cancer, the estimated pCR rate increased from 29% with standard therapy to 53% with the dual-immunotherapy regimen. In hormone receptor–positive, HER2-negative disease, the rate rose from 14% to 36%. These results suggest that combined checkpoint inhibition may have activity beyond tumors traditionally considered most responsive to immunotherapy. However, the study was not designed to establish definitive survival advantages, and the investigators emphasized that the exact regimen should not be adopted as a new standard based on these findings alone.
Tumor biology appeared to influence the magnitude of response. Patients whose tumors were positive for ImPrint, a 53-gene test designed to identify an immune-responsive tumor environment, experienced particularly high pCR rates after receiving the experimental treatment. The estimated rate reached 83% among ImPrint-positive patients with triple-negative disease and 91% among those with hormone receptor–positive, HER2-negative tumors. ImPrint-positive tumors show gene-expression patterns associated with immune-cell activity and a microenvironment that may be more receptive to immune stimulation. The findings support the broader goal of matching immunotherapy to the molecular features of each patient’s tumor.
The safety results nevertheless placed important limits on the treatment’s future development. Decreased adrenal hormone production occurred in 21% of patients receiving the dual-checkpoint combination, including grade 3 or 4 events in 11%. Diabetes developed in 4% of participants. These endocrine toxicities can require long-term hormone replacement or specialist care, and some emerged weeks after immunotherapy had ended. The delayed timing illustrates why patients receiving checkpoint inhibitors need continued monitoring after treatment, even when chemotherapy and surgery have been completed. The investigators concluded that the efficacy signal was compelling but that the toxicity profile was too concerning for the regimen to advance unchanged.
Claudine Isaacs, MD, lead author and associate director for clinical research at Georgetown’s Lombardi Comprehensive Cancer Center, said the results establish a proof of principle for targeting two immune checkpoints at once. Future studies may examine different doses, schedules, or newer drugs designed to hit both pathways with a potentially lower toxicity burden. One possibility is the use of bispecific antibodies, engineered molecules that bind two targets through a single drug. The I-SPY2 platform, which has enrolled more than 2,500 patients and tested 25 therapies over approximately 15 years, will continue evaluating treatment combinations and molecular tests intended to maximize benefit while limiting unnecessary harm.
Subject of Research: People
Article Title: Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer: The I-SPY2 Randomized Clinical Trial
News Publication Date: 30-Jul-2026
Web References: https://doi.org/10.1001/jamaoncol.2026.2576; ClinicalTrials.gov identifier NCT01042379
References: JAMA Oncology, DOI: 10.1001/jamaoncol.2026.2576
Keywords: breast cancer, HER2-negative breast cancer, ERBB2, immunotherapy, cemiplimab, fianlimab, PD-1, LAG-3, neoadjuvant chemotherapy, pathologic complete response, I-SPY2, precision medicine
Tags: adaptive I-SPY2 trialcombination immunotherapyearly breast cancer treatment strategiesHER2-negative breast cancerhigh-risk early-stage breast cancerhormone receptor–positive HER2-negative breast cancerimmune-related toxicities in cancer treatmentimmunotherapy in breast cancerneoadjuvant chemotherapytargeting immune-suppressive pathwaystriple-negative breast cancertumor eradication with immunotherapy
